Linker histone regulates the myeloid versus lymphoid bifurcation of multipotent hematopoietic stem and progenitors
- PMID: 41118213
- DOI: 10.1073/pnas.2509412122
Linker histone regulates the myeloid versus lymphoid bifurcation of multipotent hematopoietic stem and progenitors
Abstract
Myeloid-biased differentiation of multipotent hematopoietic stem and progenitor cells (HSPCs) occurs with aging or exhaustion. The molecular mechanism(s) responsible for this fate bias remain unclear. Here, we report that linker histone regulates HSPC fate choice at the lymphoid versus myeloid bifurcation. Linker histones package nucleosomes and compact chromatin. HSPCs expressing a doxycycline (dox)-inducible H1.0 transgene favor the lymphoid fate, display strengthened nucleosome organization, and reduced chromatin accessibility at subsets of genomic regions. The genomic regions showing reduced chromatin accessibility host many known marker genes of myeloid-biased HSCs. The transcription factor Hlf is located in one of the most differentially closed regions, whose chromatin accessibility and gene expression are reduced in H1.0high HSPCs. Failure to reduce Hlf expression in multipotential HSPCs abrogates the H1.0-endowed lymphoid potential. Furthermore, HSPCs display aspartyl protease-dependent H1.0 decreases, especially in response to interferon alpha (IFNα). Aspartyl protease inhibitors preserve endogenous H1.0 levels and promote the lymphoid fate of wild type HSPCs. Thus, our work elucidates a molecular scenario of how myeloid bias arises and uncovers a point of intervention for correcting myeloid skewed hematopoiesis.
Keywords: inflammation; linker histone; myeloid bias.
Conflict of interest statement
Competing interests statement:The authors declare no competing interest.
Update of
- 
  
  Linker histone regulates the myeloid versus lymphoid bifurcation of multipotent hematopoietic stem and progenitors.bioRxiv [Preprint]. 2024 Sep 17:2024.09.16.613227. doi: 10.1101/2024.09.16.613227. bioRxiv. 2024. Update in: Proc Natl Acad Sci U S A. 2025 Oct 28;122(43):e2509412122. doi: 10.1073/pnas.2509412122. PMID: 39345411 Free PMC article. Updated. Preprint.
MeSH terms
Substances
Grants and funding
- AWD0002623/ImCORE
- DP2GM123507/HHS | NIH | OSC | Common Fund (NIH Common Fund)
- R21DK128680/HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- U54 DK106857/DK/NIDDK NIH HHS/United States
- U54 DK106829/DK/NIDDK NIH HHS/United States
- T32HL007974/HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- Finance Code 001/Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
- R56HL173442/HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- 22 round/American Society of Hematology (ASH)
- R01GM147165/HHS | National Institutes of Health (NIH)
- R01HD114814/HHS | National Institutes of Health (NIH)
LinkOut - more resources
- Full Text Sources
- Medical
 
        